Anosmia and Ageusia in Sars-Cov-2 Infection
Main Article Content
Abstract
Background: Corona infection is primarily a respiratory disease, but the SARS-CoV-2 virus also penetrates other organs, causing various symptoms, including olfactory and gustatory dysfunction, which is why we can consider COVID-19 as a multisystem disease.
Aim: To present review of some aspects of the olfactory and gustatory dysfunction in SARS-CoV- infection.
Methods: The article has an analytical character and review of the literature.
Results and Discussion: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a high similarity with SARS-CoV-1 and uses the same receptors to enter the human body (angiotensin-converting enzyme 2/ACE2). COVID-19 is primarily a disease of the respiratory system, but SARS-CoV-2 also penetrates the other organs including central nervous system (CNS). Patients with SARS-CoV-2 infection can experience a range of clinical manifestations, from no symptoms to critical illness. The entry of the virus into the brain can lead to different neurological and psychiatric manifestations, including loss of smell (anosmia) and the loss of taste (ageusia). The frequency of anosmia and ageusia in patients with COVID-19 varies widely, from 10 to 65%, being the primary symptom in about 12% of patients. For now, the etiopathogenesis of anosmia and ageusia in SARS-CoV-2 infection is still unknown. Most of the analyzed subjects reported olfactory recovery. However, anosmia and ageusia can last several months or even longer. While most patients are expected to recover their sense of smell or taste within the first three months, a major subpopulation of patients might develop long lasting dysfunction. Although a substantial proportion of patients with Covid-19 might develop long lasting of diferent level of ansomia and ageusia it is uncertain what proportion of patients develop persistent dysfunction. Anosmia/ageusia can be as an important risk factor for fog, anxiety, and depression that may show a prolonged and/or delayed impact. However, we do not yet know what long-term effects these disorders may have on the central nervous system and mental health in general.
Conclusion: The COVID-19 is primarily a disease of the respiratory system, but SARS-CoV-2 also penetrates other organs (multisystem disease), causing various symptoms, including olfactory and gustatory dysfunction. The frequency of anosmia and ageusia in patients with COVID-19 is common but according to different papaers varies widely, from 10 to 65%, being the primary symptom in about 12% of patients. Most of the analyzed subjects reported olfactory recovery. However, anosmia and ageusia can last several months or even longer. We do not yet know what long-term consequences these disorders may have on the central nervous system and mental health in general.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
DOI: 10.24869/psyd.2020.236
2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/ Accessed [April 3, 2023].
3. Desai M., Oppenheimer J. The importance of considering olfactory dysfunction during the COVID-19 pandemic and in clinical practice. J Allergy Clin Immunol. 2021; 9: 7-12. 10.1016/j.jaip.2020.10.036
4. Haehner A, Marquardt B, Kardashi R et al. SARS-CoV-2 leads to significantly more severe olfactory loss than other seasonal cold viruses. Life-Basel 2022; 12:8. 10.3390/life12030461
5. Goncalves S, Goldstein BJ. Pathophysiology of olfactory disorders and potential treatment strategies. Curr Otorhinolaryngol Rep. 2016;4(2):115–121. DOI: 10.1007/s40136016-0113-5
6. Lop Gros J, Iglesias Coma M et al. Olfactory dysfunction in COVID-19, a review of the evidence and implications for pandemic management. Acta Otorrinolaringol Esp (Engl Ed). 2020; 71(6): 379-385. DOI: 10.1016/j.otorri.2020.04.003
7. Holbrook EH, Leopold DA. Anosmia: diagnosis and management. Curr Opin Otolaryngol Head Neck Surg. 2003;11(1): 54-60. DOI: 10.1097/00020840-200302000-00012
8. Cowart Bl, Young M, Feldman RS, Lowry LD. Clinical disorders of smell and taste. Occup Med 1997; 12:465-483.
9. Lee DY, Lee WH, Wee JH et al. Prognosis of postviral olfactory loss: follow-up study for longer than one year. Am J Rhinol Allergy. 2014; 28: 419-422. DOI: 10.2500/ajra.2014.28.4102
10. Welge-Lüssen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006; 63(5):125-132. DOI: 10.2500/ ajra.2014.28.4102
11. Pellegrino R, Walliczek-Dworschak U, Winter G, Hull D, Hummel T. Investigation of chemosensitivity during and after an acute cold. Int Forum Allergy Rhinol. 2017; 7(2):185-191. DOI: 10.1002/ alr.21869
12. Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci 2020;35(18):e174. DOI: 10.3346/jkms.2020.35.e174 19. Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: report of a case. Acta Neurol Taiwan. 2006;15(1):26–28. PMID: 16599281
13. Sinanović O. Olfactory and Gustatory Dysfunction in Patients with COVID-19. Sci Arts Relig. 2022; 1(2-4):229-236.
14. Rocke J, Hopkins C, Philpott C, Kumar N.Is loss of sense of smell a diagnostic marker in COVID-19: a systematic review and meta-analysis. Clin Otolaryngol. 2020; 45(6):914-922.
15. Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol. 2020; 277(8): 2251–2261.
16. Gary JB, Gallagher L, Joseph PV, Reed D, Gudis DA, Overdevest JB. Qualitative Olfactory Dysfunction and COVID-19: An Evidence-Based Review with Recommendations for the Clinician. Am J Rhinol Allergy. 2023; 37(1): 95-101.
17. Machado C, Gutierrez J. Anosmia and ageusia as initial or unique symptoms after SARS-COV-2 virus infection. Preprints 2020;2020040272. DOI: 10.20944/preprints202004.0272.v1
18. Menni C, Valdes AM, Freidin MB et al.Real-time tracking of self-reported symptoms to predict potential COVID-19.Nat Med. 2020; 26(7): 1037–1040.
19. Azizi SA, Azizi SA. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. J Neurovirol. 2020; 26: 631–641. 10.1007/s13365-020-00903-7
20. Wei GL, Gu JL, Gu ZC et al. Olfactory dysfunction in patients with coronavirus disease 2019: a review. Front Neurol. 2022; 12:783249. 10.3389/fneur.2021.783249
21. Mao L, Jin H, Wang M et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1-9. DOI: 10.1001/ jamaneurol.2020.1127
22. Boscolo-Rizzo P, Menegaldo A, Fabbris C et al. Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19. Chem Senses. Published online2021;46. doi: 10.1093/chemse/bjab006
23. Boscolo-Rizzo P, Guida F, Polesel J et al. Self-reported smell and taste recovery in COVID-19 patients: a one-year prospective study. medRxiv. Published online2021. doi: 10.1101/2021.03.18.21253862
24. Hopkins C, Surda P, Vaira LA et al. Six month follow-up of self-reported loss of smell during the COVID-19 pandemic. Rhinol J. 2021; 59(1): 26–31.
25. Niklassen AS, Draf J, Huart C et al. COVID-19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste. Laryngoscope. 2021; 131(5):1095-1100. doi: 10.1002/lary.29383.
26. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol-Head Neck Surg. 2020; 163(1): 3–11.
27. Ibekwe TS, Fasunla AJ, Orimadegun AE. Systematic review and meta-analysis of smell and taste disorders in COVID-19. OTO Open. 2020; 4(3): 1–13.
28. Koyama S, Mori E, Ueha R. Insight into the mechanisms of olfactory dysfunction by COVID-19. Auris Nasus Larynx. 2022 Dec 9 doi: 10.1016/j.anl.2022.12.002
29. Delgado-Losada ML, Bouhaben J, Ruiz-Huerta C et al. Long-Lasting Olfactory Dysfunction in Hospital Workers Due to COVID-19: Prevalence, Clinical Characteristics, and Most Affected Odorants. Int J Environ Res Public Health. 2022 May 9; 19(9): 5777. doi: 10.3390/ijerph19095777.
30. Koyama S, Ueha R, Kondo K. Loss of smell and taste in patients with suspected COVID-19: analyses of patients’ reports on social media. J Med Internet Res. 2021; 23(4): e26459.
31. Beltrán-Corbellini A, Chico-García JL, Martínez-Poles J et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study. Eur J Neurol. 2020; 27(9): 1738-1741.
32. Wong DKC, Gendeh HS, Thong HK et al. A review of smell and taste dysfunction in COVID-19 patients. Med J Malaysia. 2020; 75(5): 574-581.
33. von Bartheld CS, Hagen MM, Butowt R. Prevalence of chemosensory dysfunction in COVID‐19 patients: A systematic review and meta‐analysis reveals significant ethnic differences. ACS Chemical Neuroscience. 2020; 11(19): 2944-2961.
34. Al-Ani RM, Acharya D. Prevalence of anosmia and ageusia in patients with COVID-19 at a primary health center, Doha, Qatar. Indian J Otolaryngol Head Neck Surg. 2022; 74(Suppl 2): 2703-2709.
35. Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020; 277(8): 2251-2261.
36. Shrestha S, Paudel A, Shrestha S et al. Prevalence of Loss of Smell and Loss of Taste in COVID-19 Infected Patients. J Nepal Health Res Counc; 2022; 20(1): 84-88.
37. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021; 92:55–70.
38. Rochmawati E, Iskandar AC, Kamilah F. Persistent symptoms among post-COVID-19 survivors: A systematic review and meta-analysis. J Clin Nurs. 2022 Nov 25. doi: 10.1111/jocn.16471.
39. Galluzzi F, Rossi V, Bosetti C, Garavello W. Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection. Neuroepidemiology. 2021;55(2):154-161.
40. Vaira LA, De Vito A, Lechien JR, Chiesa-Estomba CM, Mayo-Yanez M, Calvo-Henriquez C et al. New onset of smell and taste loss are common findings also in patients with symptomatic COVID-19 after complete vaccination. Latryngoscope 2022; 132 (2): 419-421.
41. Moraschini V, Reis D, Sacco R, Calasans‐Maia MD. Prevalence of anosmia and ageusia symptoms among long‐term effects of COVID‐19. Oral Dis. 2021 May 31: 10.1111/odi.13919.
42. Al-Ani RM. Smell and taste abnormalities due to COVID-19. Al-Anbar Med J. 2020; 16(1): 1-2.
43. Zhou P, Yang X-L, Wang X-G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273.
44. Suliburska J, Duda G, Pupek-Musialik D. The influence of hypotensive drugs on the taste sensitivity in patients with primary hypertension. Acta Pol Pharm. 2012; 69(1): 121-127.
45. Small DM, Prescott J. Odor/taste integration and the perception of flavor. Exp Brain Res. 2005; 166(3-4): 345-357.
46. Khani E, Khiali S, Beheshtirouy S et al. Potential pharmacologic treatments for COVID-19 smell and taste loss: a comprehensive review. Eur J Pharmacol. 2021;912:174582. DOI: 10.1016/j. ejphar.2021.174582
47. Lee JC, Nallani R, Cass L, Bhalla V, Chiu AG, Villwock JA. A systematic review of the neuropathologic findings of post-viral olfactory dysfunction: implications and novel insight for the COVID-19 pandemic. Am J Rhinol Allergy. 2021;35(3):323–333.
48. Lechien JR, Chiese – Estombia CM, De Siati DR, Horoi M, Le Bon SD, Rodrigez A et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol. 2020; 1:1-11.
49. Kye Jyn Tan BK, Han R, Zhao J, Kye Wen Tan N et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022 Jul 27; 378: e069503. doi: 0.1136/bmj-2021-069503.
50. Santos REA, da Silva MG, do Monte Silva MCB et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: A systematic review. Am J Otolaryngol 2021; 42: 102889. 10.1016/j.amjoto.2020.102889
51. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2020; 95: 1621-1631.
52. Logue JK, Franko NM, McCulloch DJ et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open 2021;4:e210830. 10.1001/jamanetworkopen.2021.0830
53. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397: 220-232.
54. Xydakis MS, Albers MW, Holbrook EH et al. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021; 20: 753-761.